Please login to the form below

Not currently logged in
Email:
Password:

Hutchison China Medipharma signs research agreement with Eli Lilly

China-headquartered pharmaceutical company, Hutchison China Meditech, has revealed that its Hutchison MediPharma (HMPL) unit agreed a research collaboration with US-based Eli Lilly to co-develop oncology and anti-inflammatory medicines.

China-headquartered pharmaceutical company, Hutchison China Meditech, has revealed that its Hutchison MediPharma (HMPL) unit agreed a research collaboration with US-based Eli Lilly to co-develop oncology and anti-inflammatory medicines.

Hutchison will be awarded milestone payments of between USD 20m and USD 29m according to the type of clinical candidate. The company will also receive an upfront fee, annual R&D support costs, as well as also potential royalties.

Per the agreement, Hutchison will take responsibility for initial R&D, while Eli Lilly will offer technological advice and clinical trial expertise as the project develops.

Hutchison said that the research will be based in China to reduce overall costs.

In July 2007, Lilly revealed that the Oncologic Drugs Advisory Committee of the FDA had voted to recommend approval of its osteoporosis drug Evista (raloxifene) for a new use to reduce invasive breast cancer risk in post-menopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.

Lilly's cancer pipeline includes enzastaurin for brain cancer, which it intends to submit to the FDA in 2008, as well as arzoxifene for osteoporosis and prevention of breast cancer for submission in 2009.

HMPL currently has clinical programmes in preclinical and discovery stages to study its leading oncology candidate, a radio sensitiser, in multiple types of cancers, including non-small cell lung cancer (NSCLC) and head and neck cancer. The company's discovery research is focused on specific oncological and haematological targets with a full panel of in-vitro and in-vivo assays.

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...
NHS Long Term Plan - Digital is firmly on the agenda. Are you ready?
The message is clear. To keep pace with the NHS, pharma and healthcare companies must act now and refine their digital strategy to meet the needs of a transforming NHS....

Infographics